Treatment News : Merck Terminates Development of Its HIV Entry Inhibitor, Vicriviroc

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 15, 2010

Merck Terminates Development of Its HIV Entry Inhibitor, Vicriviroc

Merck announced July 14 that it is abandoning development of vicriviroc, the company’s CCR5-blocking HIV entry inhibitor candidate. In a statement, Merck explained: “This decision was based on the overall clinical data from Phase III trials in treatment-experienced patients and a recently completed Phase II trial in treatment-naive patients.”

Data from the Phase III treatment-experienced trial referenced in Merck’s statement were reported in February at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco. In that study, vicriviroc, when combined with an optimized regimen of approved antiretroviral (ARV) drugs, failed to demonstrate its superiority to a regimen made up only of optimized drugs.

The recently completed Phase II study involved people living with HIV starting ARV therapy for the first time. It explored the safety and efficacy of vicriviroc plus Norvir (ritonavir)–boosted Reyataz (atazanavir), compared with a commonly approved regimen consisting of Norvir-boosted Reyataz plus Truvada (tenofovir and emtricitabine). Results from this clinical trial have not yet been publicly reported by the company.

An earlier Phase II study, however, was prematurely terminated in 2005 because of potential efficacy concerns among treatment-naive patients. In this clinical trial, volunteers receiving vicriviroc, paired with Combivir (zidovudine and lamivudine), were more likely to experience early viral load rebounds compared with those receiving Sustiva (efavirenz) plus Combivir.

With the termination of vicriviroc’s development, Merck has directed researchers involved in the only ongoing study involving the drug to contact all the study participants and safely switch them to a regimen containing other ARV therapies.

Search: Vicriviroc, Merck, entry inhibitor, CCR5

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.